Lilly execs move up the corporate ladder

The looming retirement of a pair of key Eli Lilly ($LLY) execs has opened the door for the advancement of several top insiders at the Big Pharma company. Dave Ricks, president of Lilly USA, is being promoted to succeed Bryce D. Carmine as senior vice president and president of Lilly Bio-Medicines. The Bio-Medicines ops encompass the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal and urology. Maria Crowe is being promoted to succeed Frank Deane as president of manufacturing operations; Alex Azar is being promoted to president of Lilly USA. Lilly release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.